logo logo
  • Inify Laboratories
    • Request a presentation
    • Prostate cancer diagnosis
  • About us
    • Words from our CEO
    • Executive team
  • News & events
    • Inify Laboratories news
    • Newsletter
    • Publications
  • Careers
  • Investors
    • Executive team
    • Board of directors
    • Sustainability
  • Contact us
    • Contact
    • Investor relations & media
logo logo
  • Start
  • Inify Laboratories
    • Request a presentation
    • Prostate cancer diagnosis
  • About us
    • Inify laboratory services
    • Words from our CEO
    • Executive team
  • Newsroom
    • News & events
    • Newsletter
    • Publications
  • Careers
  • Investors
    • Executive team
    • Board of directors
    • Sustainability
  • Contact us
    • Contact
    • Investor relations & media

Inify news

Latest news

2022-05-30 Inify Laboratories – Extended subscription period
2022-05-09 Inify Laboratories – extra bolagsstämma 2022-05-09
2022-04-11 Inify Laboratories – kallelse till extra bolagsstämma

Corporate news

2024-05-14 Bulletin from the Annual General Meeting of ContextVision AB (publ) on 14 May 2024
2024-04-12 Notice to Attend the Annual General Meeting in ContextVision AB (publ)
2023-03-30 ContextVision – Invitation to Annual General Meeting 2023
2022-03-31 ContextVision – Invitation to Annual General Meeting 2022
2022-03-31 ContextVision presents Annual Report 2021
2022-02-11 ContextVision – Information regarding dividend and reverse share split in Inify Laboratories
2022-02-02 ContextVision announces resolution regarding record date for dividend
2021-11-15 ContextVision to focus pathology efforts on the establishment of a fully AI-supported lab service
2021-10-18 INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers
2021-08-31 In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites
© Inify® Laboratories